{
    "id": 1403,
    "fullName": "MYC amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "MYC amplification indicates an increased number of copies of the MYC gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4609,
        "geneSymbol": "MYC",
        "terms": [
            "MYC",
            "bHLHe39",
            "c-Myc",
            "MRTL",
            "MYCC"
        ]
    },
    "variant": "amp",
    "createDate": "08/12/2014",
    "updateDate": "10/09/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9845,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-901 inhibited cell growth of small cell lung cancer cells harboring MYC amplification in culture (PMID: 28089889).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 1564,
                "therapyName": "TAK-901",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9840,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alisertib (MLN8237) inhibited cell growth of small cell lung cancer cells harboring MYC amplification in culture (PMID: 28089889).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10865,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a non-small cell lung carcinoma cell line harboring a MYC amplification demonstrated decreased cell viability when treated with FK866 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 5662,
                "therapyName": "FK866",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10868,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a medulloblastoma cell line harboring MYC amplification demonstrated reduced cell viability when treated with GMX1778 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 5666,
                "therapyName": "GMX1778",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21285,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient derived xenograft models of osteosarcoma with MYC amplification were sensitive to treatment with JQ1, demonstrating some tumor growth inhibition (PMID: 30266815).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2209,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775) inhibited flank tumor growth in a patient-derived xenograft model of glioblastoma multiforme (GBM) with MYC amplification, but had no efficacy in brain GBM xenograft tumors due to limited distribution across the blood-brain barrier (PMID: 25609063).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2769,
                    "pubMedId": 25609063,
                    "title": "The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25609063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6516,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Farydak (panobinostat) inhibited cell survival and induced apoptosis in Myc-driven B-cell lymphoma cells in culture (PMID: 26676759).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 1080,
                "therapyName": "Panobinostat",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5674,
                    "pubMedId": 26676759,
                    "title": "Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676759"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1703,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JQ1 inhibited MYC expression and decreased cell proliferation in MYC-amplified Merkel cell carcinoma cells in culture, and inhibited tumor growth in MYC-amplified Merkel cell carcinoma xenograft models (PMID: 25277525).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 3965,
                "name": "Merkel cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1849,
                    "pubMedId": 25277525,
                    "title": "BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25277525"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5610,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, THZ1 inhibited proliferation of MYC-amplified primitive neuroectodermal tumor cell lines in culture (PMID: 25416950).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 3908,
                "therapyName": "THZ1",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5125,
                    "pubMedId": 25416950,
                    "title": "CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25416950"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9916,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-907 inhibited growth of diffuse large B-cell lymphoma cell lines with MYC amplification in culture (PMID: 27980108).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 709,
                "therapyName": "CUDC-907",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7758,
                    "pubMedId": 27980108,
                    "title": "Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27980108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2210,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775) inhibited flank tumor growth in a patient-derived xenograft model of glioblastoma multiforme (GBM) with MYC amplification, but had no efficacy in brain GBM xenograft tumors due to limited distribution across the blood-brain barrier (PMID: 25609063).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 3073,
                "name": "brain glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2769,
                    "pubMedId": 25609063,
                    "title": "The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25609063"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10859,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived glioblastoma cells harboring MYC amplification demonstrated decreased cell viability and cell proliferation, and increased apoptotic activity when treated with FK866 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 5662,
                "therapyName": "FK866",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8790,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 100% (6/6) of small cell lung cancer cell lines harboring MYC amplification demonstrated either strong or intermediate sensitivity to Barasertib (AZD1152) in culture (PMID: 27496133).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 662,
                "therapyName": "Barasertib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6752,
                    "pubMedId": 27496133,
                    "title": "Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27496133"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9855,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Birabresib (OTX015) resulted in decreased MYC expression and reduced proliferation of a non-small cell lung cancer line with MYC amplification in culture (PMID: 27835869).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 2034,
                "therapyName": "Birabresib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7708,
                    "pubMedId": 27835869,
                    "title": "OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27835869"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21281,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient derived xenograft (PDX) models with MYC amplification were sensitive to treatment with AT7519, demonstrating decreased tumor growth, apoptotic activity, and 30% tumor shrinkage in 3/8 models (PMID: 30266815).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 2727,
                "therapyName": "AT7519",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1704,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JQ1 inhibited MYC expression and decreased viability of MYC-amplified medulloblastoma cells in culture, and increased survival in MYC-amplified medulloblastoma xenograft models (PMID: 24297863).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1850,
                    "pubMedId": 24297863,
                    "title": "BET bromodomain inhibition of MYC-amplified medulloblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24297863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21286,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells from a patient derived xenograft (PDX) model of osteosarcoma with MYC amplification did not demonstrate increased apoptotic activity compared to control, but did show decreased cell viability when treated with I-BET151 in culture (PMID: 30266815).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 5953,
                "therapyName": "I-BET151",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9917,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-907 inhibited tumor growth in a patient-derived xenograft (PDX) model of esophageal cancer with MYC amplification (PMID: 27980108).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 709,
                "therapyName": "CUDC-907",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7758,
                    "pubMedId": 27980108,
                    "title": "Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27980108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10866,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring MYC amplification were sensitive to GMX1778, demonstrating decreased cell viability in culture, and inhibition of tumor growth and elevated apoptotic activity in cell line xenograft models (PMID: 27076630).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 5666,
                "therapyName": "GMX1778",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9847,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Alisertib (MLN8237) and Vepesid (etoposide) resulted in reduced cell viability in small cell lung cancer cell lines in culture (PMID: 28089889).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 5253,
                "therapyName": "Alisertib + Etoposide",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9919,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-907 inhibited tumor growth in a patient-derived xenograft (PDX) model of colorectal cancer with MYC amplification (PMID: 27980108).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 709,
                "therapyName": "CUDC-907",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7758,
                    "pubMedId": 27980108,
                    "title": "Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27980108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21282,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient derived xenograft (PDX) models of osteosarcoma with MYC amplification were sensitive to treatment with Dinaciclib (SCH 727965), demonstrating tumor growth inhibition (PMID: 30266815).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 719,
                "therapyName": "Dinaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 858,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Istodax (romidepsin) inhibited cell growth of neuroblastoma cell lines with Myc amplification (PMID: 20404560).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 1075,
                "therapyName": "Romidepsin",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 515,
                    "pubMedId": 20404560,
                    "title": "Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20404560"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11800,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, esophageal cancer cells with MYC amplification demonstrated sensitivity to Imbruvica (ibrutinib), resulting in reduced MYC expression, cell-cycle arrest, and decreased survival in culture (PMID: 28830912).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 4878,
                "name": "esophageal adenoid cystic carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9793,
                    "pubMedId": 28830912,
                    "title": "Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28830912"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10860,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived glioblastoma cells harboring MYC amplification demonstrated decreased cell viability and cell proliferation, and increased apoptotic activity when treated with GMX1778 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 5666,
                "therapyName": "GMX1778",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2212,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Adavosertib (MK-1775) and Temodar (temozolomide) demonstrated anti-tumor activity in flank tumors in a patient-derived xenograft model of glioblastoma multiforme with MYC amplification, but had limited efficacy in brain tumor xenografts (PMID: 25609063).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 2713,
                "therapyName": "Adavosertib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2769,
                    "pubMedId": 25609063,
                    "title": "The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25609063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6515,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Istodax (romidepsin) inhibited cell survival and induced apoptosis in Myc-driven B-cell lymphoma cells in both cell culture and xenograft models (PMID: 26676759).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 1075,
                "therapyName": "Romidepsin",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5674,
                    "pubMedId": 26676759,
                    "title": "Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676759"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21283,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient derived xenograft (PDX) models of osteosarcoma with MYC amplification were sensitive to treatment with Alvocidib (flavopiridol), demonstrating tumor growth inhibition (PMID: 30266815).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 628,
                "therapyName": "Alvocidib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5612,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, THZ1 inhibited proliferation of MYC-amplified lung small cell carcinoma cell lines in culture and suppressed tumor growth in MYC-amplified human small cell lung cancer cell line xenograft models (PMID: 25490451).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 3908,
                "therapyName": "THZ1",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5126,
                    "pubMedId": 25490451,
                    "title": "Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25490451"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10867,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a medulloblastoma cell line harboring MYC amplification demonstrated reduced cell viability when treated with FK866 in culture (PMID: 27076630).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 5662,
                "therapyName": "FK866",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8871,
                    "pubMedId": 27076630,
                    "title": "Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27076630"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9918,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-907 inhibited tumor growth in a patient-derived xenograft (PDX) model of non-small cell lung cancer with MYC amplification (PMID: 27980108).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 709,
                "therapyName": "CUDC-907",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7758,
                    "pubMedId": 27980108,
                    "title": "Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27980108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9843,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ilorasertib (ABT-348) inhibited cell growth of small cell lung cancer cells harboring MYC amplification in culture (PMID: 28089889).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 975,
                "therapyName": "ABT-348",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9844,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CYC116 inhibited cell growth of small cell lung cancer cells harboring MYC amplification in culture (PMID: 28089889).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 711,
                "therapyName": "CYC116",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1741,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Dinaciclib (SCH 727965) demonstrated efficacy by promoting apoptosis of cultured cells and tumor regression in cell line xenograft models of triple-negative breast cancer over expressing MYC (PMID: 22430491).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 719,
                "therapyName": "Dinaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1993,
                    "pubMedId": 22430491,
                    "title": "MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22430491"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1822,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MYC amplification led to BEZ235 resistance in PIK3CA H1074R expressing human breast tumor cells in culture (PMID: 21876152).",
            "molecularProfile": {
                "id": 3606,
                "profileName": "MYC amp PIK3CA H1047R"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2233,
                    "pubMedId": 21876152,
                    "title": "PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21876152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3672,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Nerlynx (neratinib) treatment resulted in reduced tumor size and improved clinical performance for 11 months in a patient with triple-receptor negative breast cancer which harbored ERBB2 L755S, along with APC I1307K, MDM2 amplification and MYC amplification (PMID: 26358790).",
            "molecularProfile": {
                "id": 14286,
                "profileName": "APC I1307K ERBB2 L755S MDM2 amp MYC amp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3948,
                    "pubMedId": 26358790,
                    "title": "HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26358790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3673,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Nerlynx (neratinib) and Xeloda (capecitabine) combination treatment resulted in continued clinical performance improvement following progression on Neratinib (HKI-272) monotherapy in a patient with triple-receptor negative breast cancer that harbored ERBB2 L755S, along with APC I1307K, MDM2 amplification, and MYC amplification (PMID: 26358790).",
            "molecularProfile": {
                "id": 14286,
                "profileName": "APC I1307K ERBB2 L755S MDM2 amp MYC amp"
            },
            "therapy": {
                "id": 1543,
                "therapyName": "Capecitabine + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3948,
                    "pubMedId": 26358790,
                    "title": "HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26358790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4859,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FTI-277 treatment inhibited Rheb signaling and lead to cell death in lymphoma cell lines in culture, independent of the Myc amplification and Pten-deficiency (PMID: 18708578).",
            "molecularProfile": {
                "id": 19397,
                "profileName": "MYC amp PTEN dec exp"
            },
            "therapy": {
                "id": 1683,
                "therapyName": "FTI-277",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4861,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FTI-277 treatment inhibited proliferation of lymphoma cell lines harboring MYC amplification, PTEN deficiency, and overexpressing RHEB Q64L in culture (PMID: 18708578).",
            "molecularProfile": {
                "id": 19400,
                "profileName": "MYC amp PTEN dec exp RHEB Q64L"
            },
            "therapy": {
                "id": 1683,
                "therapyName": "FTI-277",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4862,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FTI-277 treatment did not inhibit proliferation of lymphoma cell lines harboring MYC amplification, PTEN deficiency, and overexpressing RHEB Q64L and RHEB M184L in culture (PMID: 18708578).",
            "molecularProfile": {
                "id": 19401,
                "profileName": "MYC amp PTEN dec exp RHEB Q64L RHEB M184L"
            },
            "therapy": {
                "id": 1683,
                "therapyName": "FTI-277",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4863,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FTI-277 treatment did not inhibit proliferation of lymphoma cell lines harboring MYC amplification, PTEN deficiency, and overexpressing Mcl1 in culture (PMID: 18708578).",
            "molecularProfile": {
                "id": 19402,
                "profileName": "MCL1 over exp MYC amp PTEN dec exp"
            },
            "therapy": {
                "id": 1683,
                "therapyName": "FTI-277",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4864,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FTI-277 treatment inhibited proliferation of lymphoma cell lines harboring MYC amplification, ARF deletion, and overexpressing RHEB Q64L and RHEB M184L in culture (PMID: 18708578).",
            "molecularProfile": {
                "id": 19403,
                "profileName": "ARF1 del MYC amp RHEB Q64L RHEB M184L"
            },
            "therapy": {
                "id": 1683,
                "therapyName": "FTI-277",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7613,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 10058-F4 inhibited growth of multiple myeloma cell lines with MYC amplification and over expression in culture (PMID: 26087190).",
            "molecularProfile": {
                "id": 25920,
                "profileName": "MYC amp MYC over exp"
            },
            "therapy": {
                "id": 3304,
                "therapyName": "10058-F4",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6444,
                    "pubMedId": 26087190,
                    "title": "MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26087190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10800,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, analysis of radiation-associated breast angiosarcoma patients treated with Nexavar (sorafenib) demonstrated complete response in 22% (2/9) and partial response in 11% (1/9) of patients, with 30% (3/10) of the total group and 2 of 3 responders (3rd not evaluated) demonstrating FLT4 (VEGFR3) and MYC co-amplification (J Clin Oncol 30, 2012 (suppl; abstr 10019)).",
            "molecularProfile": {
                "id": 27804,
                "profileName": "FLT4 amp MYC amp"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 4511,
                "name": "breast angiosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8825,
                    "pubMedId": null,
                    "title": "Activity of sorafenib in radiation-associated breast angiosarcomas harboring MYC and FLT4 amplifications.",
                    "url": "http://meetinglibrary.asco.org/content/92128-114"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11541,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment resulted in stable disease for a total of 15 months in a pancreatic ductal adenocarcinoma patient harboring EML4-ALK, along with CDKN2A/B deletion, MYC amplification, and TP53 L111fs (PMID: 28476735).",
            "molecularProfile": {
                "id": 28129,
                "profileName": "EML4 - ALK CDKN2A del CDKN2B del MYC amp TP53 L111fs"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9613,
                    "pubMedId": 28476735,
                    "title": "Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28476735"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11802,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, esophageal cancer cells with ERBB2 (HER2) and MYC amplification demonstrated sensitivity to Imbruvica (ibrutinib), resulting in decreased ERK phosphorylation and MYC expression, cell-cycle arrest, and decreased cell survival in culture (PMID: 28830912).",
            "molecularProfile": {
                "id": 28270,
                "profileName": "ERBB2 amp MYC amp"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9793,
                    "pubMedId": 28830912,
                    "title": "Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28830912"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20692,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, MYC amplification was identified in a non-small cell lung cancer patient harboring EGFR L861Q with primary resistance to icotinib (PMID: 31828849).",
            "molecularProfile": {
                "id": 35287,
                "profileName": "EGFR L861Q MYC amp"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17988,
                    "pubMedId": 31828849,
                    "title": "Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31828849"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1426,
            "profileName": "MYC amp",
            "profileTreatmentApproaches": [
                {
                    "id": 262,
                    "name": "BET  Inhibitor (Pan)",
                    "profileName": "MYC amp"
                },
                {
                    "id": 7761,
                    "name": "c-MYC Inhibitor",
                    "profileName": "MYC amp"
                }
            ]
        },
        {
            "id": 2364,
            "profileName": "BRAF wild-type KRAS wild-type MYC amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 3606,
            "profileName": "MYC amp PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14286,
            "profileName": "APC I1307K ERBB2 L755S MDM2 amp MYC amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19397,
            "profileName": "MYC amp PTEN dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19399,
            "profileName": "ARF1 del MYC amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19400,
            "profileName": "MYC amp PTEN dec exp RHEB Q64L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19401,
            "profileName": "MYC amp PTEN dec exp RHEB Q64L RHEB M184L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19402,
            "profileName": "MCL1 over exp MYC amp PTEN dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19403,
            "profileName": "ARF1 del MYC amp RHEB Q64L RHEB M184L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25920,
            "profileName": "MYC amp MYC over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27804,
            "profileName": "FLT4 amp MYC amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28129,
            "profileName": "EML4 - ALK CDKN2A del CDKN2B del MYC amp TP53 L111fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28270,
            "profileName": "ERBB2 amp MYC amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35287,
            "profileName": "EGFR L861Q MYC amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}